PROSPECTIVE RANDOMIZED STUDY OF CELL THERAPY FOR METASTATIC MELANOMA USING SHORT-TERM CULTURED TUMOR INFILTRATING LYMPHOCYTES PLUS IL-2 FOLLOWING EITHER A NON-MYELOABLATIVE LYMPHOCYTE DEPLETING CHEMOTHERAPY REGIMEN ALONE OR IN CONJUNCTION W/1200 TBI: